Needham Reaffirms Their Hold Rating on Tetraphase (TTPH)

By Austin Angelo

Needham analyst Alan Carr maintained a Hold rating on Tetraphase (TTPHResearch Report) on August 9. The company’s shares closed on Friday at $0.31, close to its 52-week low of $0.31.

According to TipRanks.com, Carr is a 3-star analyst with an average return of 1.8% and a 41.8% success rate. Carr covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Lexicon Pharmaceuticals.

Currently, the analyst consensus on Tetraphase is a Moderate Buy with an average price target of $1.50.

See today’s analyst top recommended stocks >>

Based on Tetraphase’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $22.92 million. In comparison, last year the company had a GAAP net loss of $9.54 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.